OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has received an average rating of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $13.4286.

A number of equities analysts recently weighed in on the company. Stephens decreased their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 13th. Stifel Nicolaus decreased their price objective on OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. B. Riley Financial decreased their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Lake Street Capital decreased their price objective on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Wall Street Zen lowered OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPRX. Quantbot Technologies LP bought a new stake in OptimizeRx during the 2nd quarter valued at $44,000. BNP Paribas Financial Markets raised its holdings in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in OptimizeRx during the 4th quarter valued at $62,000. Aaron Wealth Advisors LLC bought a new stake in OptimizeRx during the 1st quarter valued at $66,000. Finally, Hsbc Holdings PLC bought a new stake in OptimizeRx during the 1st quarter valued at $85,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $5.28 on Friday. The stock has a market cap of $99.05 million, a price-to-earnings ratio of 15.09 and a beta of 1.13. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx has a 1-year low of $4.57 and a 1-year high of $22.25. The stock’s 50-day moving average is $5.87 and its 200 day moving average is $9.00.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $19.84 million for the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. On average, sell-side analysts anticipate that OptimizeRx will post 0.51 EPS for the current fiscal year.

OptimizeRx announced that its Board of Directors has authorized a stock buyback plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.